PIG.DU - Perrigo Co PLC
Chart Events
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 29.48 |
| Open | 29.71 |
| Bid | 30.66 x N/A |
| Ask | 30.95 x N/A |
| Day's Range | 29.69 - 30.57 |
| 52 Week Range | 28.50 - 42.34 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Related Research
ZacksStryker's (SYK) Q Guidance Successful in First Surgery
Stryker (SYK) successfully completes first surgical case using its Q Guidance system with Cranial Guidance software. An Early Product Surveillance is underway for the combined technology.
ZacksDown -16% in 4 Weeks, Here's Why You Should You Buy the Dip in Perrigo (PRGO)
The heavy selling pressure might have exhausted for Perrigo (PRGO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ZacksIs Perrigo (PRGO) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo Finance VideoFTC investigating baby-formula makers on suspected collusion
Yahoo Finance health care reporter Anjalee Khemlani discusses the ongoing investigation by the FTC of baby-formula makers, including Abbott Laboratories, Perrigo, and Nestle, on suspected collusion.
PR NewswirePerrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it is scheduled to host 1x1 investor meetings at the Oppenheimer 23rd Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 13th.
ZacksIs Koninklijke Philips (PHG) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AP FinanceRecalled Gerber baby formula was sent to US retailers after recall began, wholesaler says
An infant formula recalled over potential bacteria contamination was distributed to retailers across eight states after the recall began, according to a release published by the U.S. Food and Drug Administration this week. Perrigo Co. issued a voluntary March recall of certain lots of its Gerber Good Start SoothePro Powdered Infant Formula “out of an abundance of caution” due to the possible presence of Cronobacter sakazakii, a germ that can cause serious or deadly infections in infants. The recall includes Gerber Good Start formula manufactured between Jan. 2 and Jan. 18 at the Perrigo’s Eau Claire, Wisconsin, facility.
PR NewswireCOUNTRY STAR MITCHELL TENPENNY AND PREVACID ANNOUNCE "BEAT THE BURN" - A LIVE TIK TOK CONCERT TO SING AWAY STRESS
Did you know that stress is a leading cause of frequent heartburn? Stressburn is what we like to call it and it can be prevented with Prevacid 24HR.
- PR Newswire
PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that it has received final approval from the U.S. Food and Drug Administration for Nicotine Coated Mint Lozenges, 2 mg and 4 mg over-the-counter (OTC).
The Wall Street JournalAbortion Bans Can Help Make This Cheap, Accessible Birth Control Pill a Hit
The FDA’s potential approval of an over-the-counter oral contraceptive could mean a huge market for generic drugmaker Perrigo.
The Wall Street JournalFDA Advisers Back Over-the-Counter Birth-Control Pill
Advisers to the Food and Drug Administration recommended making an oral contraceptive available without a prescription for the first time, potentially widening access to birth control for women across the country. The panel of FDA advisers voted 17 to 0 on Wednesday that there was enough evidence for the agency to approve the medication’s sale over-the-counter. The FDA, which is expected to make a final decision this summer, doesn’t have to follow the expert panel’s advice, though it often does.
Yahoo Finance VideoPerrigo stock rises amid FDA's unanimous vote on over-the-counter birth control pill
Yahoo Finance healthcare reporter Anjalee Khemlani joins the Live Show to discuss the rise of Perrigo stock after the FDA votes unanimously for over-the-counter access to the birth control pill.
BloombergFDA Panel Backs Over-The-Counter Birth Control Pill
(Bloomberg) -- Perrigo Co.’s over-the-counter Opill gained a key recommendation from US regulatory advisers, paving the way for the birth-control pill to get clearance to be sold without a prescription.Most Read from BloombergSteve Schwarzman Holds Off Giving Money to DeSantis After Meeting HimItaly Intends to Exit China Belt and Road Pact as Ties SourTucker Carlson’s Twitter Move Wipes $235 Million From RumbleUS Inflation Shows Signs of Moderating, Giving Fed Room to PauseTreasuries Advance Aft
- Reuters
UPDATE 2-U.S. FDA advisers back Perrigo birth control pill for over-the-counter use
"The benefit of Opill being available to diverse populations including adolescents and those with limited literacy is in demand," said Dr Jolie Haun, a panelist who voted in favor of the pill. On Friday, the FDA had raised concerns around the drug's studies, including whether participants were able to follow dosing instructions.
- PR Newswire
FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S. Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee (NDAC) and the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee (ORUDAC) voted unanimously 17 to 0, with no abstentions, that the benefits of making Opill®, a progestin-only daily oral contraceptive, available for over-the-counter (OTC) use outweighs the risks. The joint committee's vote, wh
AP FinanceFDA panel backs over-the-counter sales of birth control pill
Federal health advisers said Wednesday that a decades-old birth control pill should be sold without a prescription, paving the way for a likely U.S. approval of the first over-the-counter contraceptive medication. The panel of FDA advisers voted unanimously in favor of drugmaker Perrigo’s request to sell its once-a-day medication on store shelves alongside eye drops and allergy pills. The recommendation came at the close of a two-day meeting focused on whether women could safely and effectively take the pill without professional supervision.
ZacksPerrigo (PRGO) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Perrigo (PRGO) give insight into how the company performed in the quarter ended March 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
ZacksPerrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View
Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.
ZacksPerrigo (PRGO) Q1 Earnings and Revenues Top Estimates
Perrigo (PRGO) delivered earnings and revenue surprises of 7.14% and 2.16%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Perrigo Reports First Quarter Fiscal Year 2023 Financial Results From Continuing Operations
First Quarter 2023 Highlights:
- PR Newswire
Perrigo Announces Chief Executive Officer Retirement and Succession Plan
Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, today announced that Murray S. Kessler has notified the Company of his intent to retire as President and Chief Executive Officer, with a target effective date of July 31, 2023. Mr. Kessler will be working with the Board of Directors to secure his successor and to ensure a smooth transition.
ZacksViemed Healthcare, Inc. (VMD) Misses Q1 Earnings Estimates
Viemed Healthcare, Inc. (VMD) delivered earnings and revenue surprises of -42.86% and 3.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Yahoo Finance VideoU.S. regulators raise concern about Opill’s suitability as an over-the-counter drug
Yahoo Finance’s Anjalee Khemlani joins the Live show to discuss the decline in stock for Opill drugmaker Perrigo Company and why the FDA believes the abortion pill may not be suitable as an over-the-counter drug.
- Reuters
UPDATE 2-US FDA staff raises concerns over OTC use of Perrigo's birth control pill
The U.S. health regulator's reviewers on Friday raised concerns around allowing Perrigo Co's birth control drug over the counter, saying switching to non-prescription sale could lead to inappropriate usage by consumers. Perrigo's Opill, which is currently approved for prescription use, would be the first OTC non-estrogen contraceptive pill in the United States if approved. Contraceptives have been in focus since the U.S. Supreme Court last year overturned the constitutional right to terminate pregnancies as it scrapped a landmark ruling in the 1973 Roe vs. Wade case.
AP FinanceOver-the-counter birth control pill faces FDA questions
U.S. health regulators are weighing the first-ever request to make a birth control pill available without a prescription. The FDA cited problems with the reliability of some of the company’s data on the drug, Opill, and questioned whether women with certain other medical conditions would correctly opt out of taking it. Advisers to the FDA meet next week to review drugmaker Perrigo's application.
